StockWatch
·

Pajson Agro India Ltd Q2 FY27 Results

PAJSONQ2 FY27 Results
Filing
MetricValue (₹ Cr)
Revenue143.39
Total Income145.11
Expenditure128.20
PBT16.91
Net Profit12.56
OPM—
NPM8.65%
EPS5.27
View full financials
PAJSON · Q2 FY27 · THE VERDICT

Growth Beats, Margins Crack: A Transformation in Motion but Execution Unproven

Pajson beat revenue guidance by 3 points but missed margin recovery by over 100 basis points. The quarter reveals a company scaling fast into a global franchise—but quality of earnings is softening, and institutions are trimming.

13 Nov 2026 · 6 min read
Revenue (H1 FY27)

₹143.4 Cr

+23% YoY vs 20% guidance

EBITDA margin

14%

vs 15–16% prior target

Plant utilization

95%

vs 86% prior year

Institutional revenue mix

37.5%

up from 34% YoY

The headline says Pajson beat growth guidance—23% revenue versus the prior 20% steer. But step behind that: EBITDA margins fell to 14%, undershooting the 15–16% recovery target that management promised. The real story is not the beat; it's the quality miss. A company absorbing 95% of its existing 18k MT capacity while scaling institutional business to 37.5% of revenue is doing real work. But it's doing it in a margin vice: forex headwinds, freight surcharged, raw cashew prices stubborn. Management is clear-eyed about it, but didn't revise guidance downward or articulate a recovery path—and institutions have begun trimming.

Where the margin compression came from

EBITDA fell from 18% in prior-year H1 to 12–13% in current H1, per management disclosures. That 500+ basis point swing is not operational delinquency—it's macro. Plant was running at 95% utilization, the highest in the company's covered history. The issue: input costs remained elevated, forex moved adverse, and freight surcharged. Management chose to hold volume and customer relationships rather than price aggressively, which left the margin to absorb the shock. This is operationally sound but financially painful, and it means FY27's margin recovery (the prior guidance promise) now sits in question.

Management's claims vs. what holds up

H1 FY27 revenue up 23% YoY to ₹145 Cr

Supported

Delivered ₹143.4 Cr; H1 aggregate consistent with 23% claim

EBITDA margins 14% in H1, recovery on track

Overstated

14% actual vs 15–16% prior guidance; margin fell vs. FY26 H2

PAT ₹12.6 Cr, 19% growth vs. H2 prior year

Supported

Delivered PAT ₹12.6 Cr exactly; growth rate verified

95% plant utilization vs 86% prior year

Supported

Strong efficiency gains despite cost headwinds

Institutional revenue 37.5% vs 34% prior year

Supported

Channel mix improving; large food/snack conglomerates showing traction

What changed on this call

  • Margin guidance tacitly abandoned—no FY28 reconfirmation or revision announced

  • Pacific Global acquisition (60k MT Africa, share-swap) approved and transformational

  • Institutional channel jumped to 37.5% from 34%, 178 distributors across 20+ states

  • Vizianagaram greenfield delayed 45 days (cyclones); now targeting Feb or Q4 FY27 trials

  • Royal Mewa consumer brand grew from 1.36% to 4.6% of revenue; targeting 15% in 3–5 years

The market's own verdict

Pajson trades at ₹340 on a bullish trend—above its 20-, 50-, and 200-day moving averages (₹314.64, ₹271.18, and ₹208.67 respectively). The stock is up 183% off its 52-week low but sits -17% below its all-time high of ₹411.4, suggesting profit-taking from the peak. RSI of 62 is neutral—not overbought, not oversold. But ownership tells a different story: FII holdings collapsed from 0.92% to 0.00% quarter-on-quarter, and DII reduced from 10.95% to 7.63%. Promoter holding steady at 62.47%. The stock is up sharply, but institutions are trimming on the back of the result. That's a red flag: the market has already priced the bull case and is now skeptical on execution and margin recovery.

Bull-bear ledger

The case for holding
  • Revenue beat guidance by 300 bps—institutional channel at 37.5% is recurring, diversified

  • 95% plant utilization despite macro headwinds shows operational excellence

  • 113k MT combined capacity (India 18k + Vizianagaram 35k + Pacific Global 60k) by FY28 is transformational

  • Pacific Global origin-processing advantage (5–7% higher EBITDA vs India) structural tailwind

  • Management committed to 5–8% global cashew market share in 5–7 years with quantified roadmap

The case against
  • Margin guidance missed (14% vs 15–16%), tacitly abandoned, no recovery path articulated

  • Management declined FY28 EBITDA numbers—unusual caution for a call with strong operational disclosure

  • Vizianagaram already 45 days late due to cyclones; further delays risk FY28 ramp targets

  • FII/DII both trimming despite stock near ATH; institutions vote of no confidence on execution

  • Acquisition integration unproven; working capital will rise; cross-geography controls nascent

  • Geopolitical forex volatility described as 'unprecedented'; hedging costs unquantified

Risks, ranked by how much they should concern a holder

Risk register—what could derail the thesis

Margin recovery target abandoned; no FY28 EBITDA path

High

Earnings quality is softening despite 95% utilization. If margins stay at 12–13% through FY27–FY28, the case becomes growth-at-cost, not value creation.

Geopolitical forex volatility unprecedented; unhedged exposure

High

Management cited 'unprecedented' pressure; INR weakness and commodity currency swings are macro tails not in their control. Hedging costs eat margins further.

Vizianagaram commissioning delays sequential

Medium-High

Already 45 days late; further slippage post Feb/Q4 FY27 risk delays the 113k MT capacity target and FY28 margin uplift. Execution credibility stakes are high.

Pacific Global integration and working capital surge

Medium

Share-swap acquisition; minority governance unproven; farm-to-fork model will balloon working capital. Integration hiccups = cash drain, margin dilution.

Input-cost inflation persistent; pricing power constrained

Medium

Raw cashew prices remain elevated; management held volume over price. If input costs don't fall, margins stay capped and pricing power stays absent.

Concentrated African sourcing; geopolitical supply risk

Medium

Ivory Coast (Cote d'Ivoire) is world's largest raw cashew supplier but geopolitically volatile. Sourcing disruption = supply shock; Pacific Global is greenfield, untested.

The debate

What to watch next

Three catalysts that will resolve the debate
  • 1 · Vizianagaram facility trials by Feb / Q4 FY27

    The first real execution gate. Any further delays beyond Feb signal project risk. Timely commissioning is the linchpin for the 113k MT thesis and FY28 margin recovery.

  • 2 · Pacific Global consolidation and first African earnings (Jan–Feb FY27)

    Integration progress, working capital impact, and first consolidated financials will show whether the 5–7% margin uplift thesis is real or aspirational. Governance and cross-geography controls matter here.

  • 3 · Q3 FY27 margin inflection

    Will margins stay compressed at 12–13% or recover toward 15–16%? This is the single most important data point. If margins haven't recovered by Q3 (or management hasn't revised guidance), the hold becomes a sell.

Pajson is a transformation story that needs to prove itself. Revenue is beating, institutional channels are real, and the global pivot via Pacific Global is bold. But margin trends are worsening, not improving—management is cautious on forward numbers and has tacitly abandoned prior margin guidance—and institutions are already trimming. The stock is up 83% off its low but -17% from the peak; that's the market repricing risk.

Hold if you own for the long thesis, but watch the three catalysts closely. The single number to track is H2 / Q3 EBITDA margin. If it recovers toward 15–16% by Q3, the case re-rates higher. If it stays at 12–13%, the transformation is costlier than advertised, and re-rating comes only when Africa adds scale. This is a 2–3 year view, not a quick trade.

Informational and educational content only. Not investment advice.